Please use this identifier to cite or link to this item:
|Title:||EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs.|
|Authors:||Macdonald, Joanna;Henri, Justin;Roy, Kislay;Hays, Emma;Bauer, Michelle;Veedu, Rakesh Naduvile;Pouliot, Normand;Shigdar, Sarah|
|Affiliation:||School of Medicine, Deakin University, Geelong, VIC 3128, Australia|
Centre for Comparative Genomics, Murdoch University, Perth, WA, Australia
Perron Institute for Neurological and Translational Science, Perth, WA, Australia
Department of Pathology and University of Melbourne, Melbourne, VIC , Australia
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
Matrix Microenvironment and Metastasis Laboratory, Olivia Newton-John Cancer Research Institute, School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia
Centre for Molecular and Medical Research, Deakin University, Geelong, VIC, Australia
|Citation:||Cancers 2018; 10(1): e19|
|Abstract:||The epithelial cell adhesion molecule (EpCAM), or CD326, was one of the first cancer associated biomarkers to be discovered. In the last forty years, this biomarker has been investigated for use in personalized cancer therapy, with the first monoclonal antibody, edrecolomab, being trialled in humans more than thirty years ago. Since then, several other monoclonal antibodies have been raised to EpCAM and tested in clinical trials. However, while monoclonal antibody therapy has been investigated against EpCAM for almost 40 years as primary or adjuvant therapy, it has not shown as much promise as initially heralded. In this review, we look at the reasons why and consider alternative targeting options, such as aptamers, to turn this almost ubiquitously expressed epithelial cancer biomarker into a viable target for future personalized therapy.|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.